Survival Rate and Factors Affecting on Survival of Early-Stage Epithelial Ovarian Cancer Patients at Sawanpracharak Hospital
Keywords:
early-stage epithelial ovarian cancer, survival rate, prognostic factorsAbstract
Background and Objective: Although the survival rate of early-stage epithelial ovarian cancer is higher than advanced-stage cancer, approximately 20% to 30% of these patients succumb to the disease. The main objective is to study the 5-year survival rate, with secondary objectives focusing on factors influencing the survival of patients with early-stage epithelial ovarian cancer.
Methods: This research is a retrospective cohort study of a population comprising patients diagnosed with early-stage epithelial ovarian cancer who received treatment at Sawanpracharak Hospital between January 1, 2008, and December 31, 2018. Data were collected from medical records, and statistical analysis involved descriptive statistics, Kaplan-Meier survival curve, Log-rank test, and Cox proportional hazard model with a significance level set at p < 0.05.
Results: Among 151 patients with early-stage epithelial ovarian cancer, with a median follow-up time of 101 months, the 5-year disease-free and overall survival rates were 79.3% and 80.2%, respectively. Stage 1 ovarian cancer had a 5-year disease-free and overall survival rate of 81.3% and 83.4%, while stage 2 had rates of 71.9% and 71.7%, respectively. In the multivariate analysis, the results indicate that ECOG PS 2,3 (HR 8.84, 95% CI 2.88-27.07, p=0.001), (HR 10.68, 95% CI 3.99-28.57, p<0.001), and clear cell cancer (HR 9.01, 95% CI 1.91-42.39, p=0.005), (HR 5.16, 95% CI 1.44-18.49, p=0.012), serve as independent predictive factors for a poorer 5-year disease-free survival (DFS) and overall survival (OS). Women who were administered the carboplatin regimen (HR 5.79, 95% CI 1.12-29.61, p=0.036) and the carboplatin plus cyclophosphamide regimen (HR 3.64, 95% CI 1.22-10.89, p=0.021) exhibited lower 5-year progression-free survival (PFS) and 5-year OS compared to those who received the carboplatin plus paclitaxel regimen, respectively.
Conclusion: Early-stage epithelial ovarian cancer demonstrates favorable disease-free and overall survival rates when treated with adequate surgery and chemotherapy.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian
cancer/Fallopian Cancer/Primary Peritoneal Cancer. Version 1.2021. Available at: https://www.nccn.org/professionals/physician_gls(Accessed on January 29, 2020).
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176-82. DOI: 10.1016/S0140-6736(00)03590-X.
Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer. A Gynecologic Oncology Group Study. Cancer 2008(10);112:2202-10. doi: 10.1002/cncr.23390
Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian cancer. J Clin Oncol 1996;14(11):2968-75. doi: 10.1200/JCO.1996.14.11.2968.
Schueler JA, Cornelisse CJ, Hermans J, Trimbos JB, van der Burg ME, Fleuren GJ. Prognostic factors in well-differentiated early-stage ovarian cancer. Cancer 1993;71(3):787-95. doi: 10.1002/1097-0142(19930201)71:3<787::aid-cncr2820710322>3.0.co;2-2.
Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75(2):263-73. PMID: 2300355.
Sjovall K, Nilsson B, Einhorn N. Different types of rupture of the tumour capsule and the impact on survival in early ovarian cancer. Int J Gynecol Cancer 1994;4(5):333-6. doi: 10.1046/j.1525-1438.1994.04050333.x
Sevelda P, Dittich C, Salzer H. Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol 1989;35(3):321-2. doi: 10.1016/0090-8258(89)90071-1
Tognon G, Carnazza M, Ragnoli M, Calza S, Ferrari F, Gambino A, et al. Prognostic factors in early-stage ovarian cancer. Ecancermedicalscience 2013;7:325. doi: 10.3332/ecancer.2013.325.
Hsieh SF, Lau HY, Wu HH, Hsu HC, Twu NF, Cheng WF. Prognostic factors of early-stage epithelial ovarian carcinoma. Int J Environ Res Public Health 2019;16(4):637. doi: 10.3390/ijerph16040637
Wei W, Li N, Sun Y, Li B, Xu L, Wu L, et al. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer. Oncotarget 2016;118(14):23862-70. doi: 10.18632/oncotarget.13317
Manchana T, Kobwitaya K. Survival outcomes for different subtypes of epithelial ovarian cancer. Clin Res Obstetr Gynecol 2018;1(1):1-7.
Schnack TH, Høgdall E, Nedergaard L, Høgdall C. Demographic clinical and prognostic factors of primary ovarian adenocarcinomas of serous and clear cell histology-A comparative study. Int J Gynecol Cancer 2016;26(1):82-90. doi: 10.1097/IGC.0000000000000585.
Thaweekul Y, Lertkhachonsuk R, Khemapech N, Manchana T, Sirisabya N, Worasethsin P, et al. Treatment outcome of stage Ic ovarian clear cell carcinoma compared to non-clear cell type. Chulalongkorn Medical Journal 2010;54(3):213-23. doi: CHULA.CMJ.54.3.4
Salazar C, Campbell IG, Gorringe KL. When Is "Type I" ovarian cancer not "Type I"? Indications of an out-dated dichotomy. Front Oncol 2018;21(8):654. doi: 10.3389/fonc.2018.00654.
Ditto A, Maggiore UL, Bogani G, Martinelli F, Chiappa V, Evangelista MT, et al. Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. Int J Gynecol Obstet 2019;145(1):28-33. doi: 10.1002/ijgo.12769. Epub 2019 Feb 15.
Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003;95(2):113–25. PMID: 12529344
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88(11):2584-9. PMID: 10861437
Adams G, Zekri J, Wong H, Walking J, Green JA. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG 2010;117(12):1459-67. doi: 10.1111/j.1471-0528.2010.02635.x
Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, et al. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. J Ovarian Res 2013;6(1):42. doi: 10.1186/1757-2215-6-42
Bun S, Yunokawa M, Ebata T, Kato MK, Shimoi T, Kato T, et al. Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: A retrospective study. Int J Clin Oncol 2019;24(9):1111-8. doi: 10.1007/s10147-019-01449-3
Fourcadier E, Tretarre B, Gras-Aygon C, Ecarnot F, Daures J, Bessaoud F. Under-treatment of elderly patients with ovarian cancer: A population-based study. BMC Cancer 2015;15:937. doi: 10.1186/s12885-015-1947-9.
Yoshikawa K, Fukuda T, Uemura R, Matsubara H, Wada T, Kawanishi M, et al. Age-related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer. Mol Clin Oncol 2018;9(3):329-34. doi: 10.3892/mco.2018.1668
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
